Navigation Links
Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
Date:11/14/2011

first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement
Some of the statements included in this press release, particularly those anticipating the outcome of clinical trials and the future business prospects for Zerenex (ferric citrate), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for Zerenex; our ability to meet anticipated development timelines for Zerenex due to clinical trial results, manufacturing capabilities or other factors; our ability to replicate in our ongoing long-term Phase 3 clinical study the efficacy and safety of Zerenex observed in the previous Phase 2 studies and the short-te
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
2. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
5. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
7. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
8. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
9. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014   Intrexon Corporation (NYSE: ... announced that it has entered into an Exclusive Channel ... of Sanofi (EURONEXT: SAN and NYSE: SNY ... specific family of its marketed Active Pharmaceutical Ingredients (APIs) ... . This collaboration will leverage Intrexon,s proprietary technology ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 Cepheid ... Flu/RSV XC, an on-demand molecular test for ... Flu B, and differentiation of RSV infection. The ... under the European Directive on In Vitro ... of tests available to eighteen. Xpert Flu/RSV XC runs ...
(Date:9/2/2014)... -- Sinovac Biotech Ltd. (NASDAQ: SVA ), a leading ... today announced that the Company,s management will participate in the ... Global Healthcare Conference, to be held at the Grand Hyatt ... Morgan Stanley Asia Pacific Healthcare Day, to be held at ... Aegis Healthcare & Technology Conference, to be held at the ...
Breaking Medicine Technology:Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 2Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 4Sinovac to Participate in Upcoming Investor Conferences 2
... VirtualScopics, Inc. (Nasdaq: VSCP ), a leading provider of ... balance (the amount remaining to be recognized from its active ... the clinical research industry), exceeds $35 million which compares to ... greater than 90% increase. The average duration of the studies ...
... Sparta Systems, Inc., the maker of TrackWise® software ... compliance solutions, today announced that Ascent Healthcare Solutions, ... has selected its TrackWise Enterprise Quality Management System ... compliance with industry regulations. Ascent will deploy ...
Cached Medicine Technology:VirtualScopics' Project Balance Exceeds a Record $35 Million 2VirtualScopics' Project Balance Exceeds a Record $35 Million 3Leading Medical Device Provider Chooses TrackWise(R) Software to Optimize Customer Complaint Handling 2Leading Medical Device Provider Chooses TrackWise(R) Software to Optimize Customer Complaint Handling 3
(Date:9/2/2014)... 2014 West Hollywood cosmetic dentist ... for Invisalign. This special offer includes a free consultation ... determine their candidacy for the procedure and answer any ... may also be eligible for the Summer Invisalign special, ... the month of August, patients who choose Invisalign will ...
(Date:9/2/2014)... Dennis Thompson HealthDay Reporter ... early or at low birth weight are at risk later ... problems that increase their risk for heart disease, according to ... children face potential lifetime disadvantages, researchers in both studies ... found that these obstacles can be overcome. Education appeared ...
(Date:9/2/2014)... 02, 2014 Moroccan Eco-Biologics’ new one-of-a-kind ... formulated, while preserving the foundation of all natural Moroccan ... and scalp problems. There is nothing similar to Vitality ... , Hair loss is a commonly encountered problem for ... for treatment have been limited to existing medications offering ...
(Date:9/2/2014)... 02, 2014 USARAD Holdings Inc. ... telemedicine solutions provider, including SecondOpinions.com® – consumer division ... technologically advanced services. The telemedicine industry pioneer is ... Kuwait. , Founded and established in 1963 as ... Shifa began as a maternity care hospital with ...
(Date:9/2/2014)... 02, 2014 The global market for ... million by 2020, growing at an estimated CAGR of ... study by Grand View Research, Inc. Peripheral vascular devices ... devices are used for treating peripheral arterial or coronary ... plaques in arteries. These devices are used to decrease ...
Breaking Medicine News(10 mins):Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 2Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 3Health News:New All Natural, Organic Hair Recovery Products by Moroccan Eco-Biologics, Restore Lost Hair with No Side Effects 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 3Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5
... who wear bifocal lenses to help them focus accurately may ... new research from Cardiff University. , The Cardiff School of ... the reasons for poor focussing among children with Downs syndrome. ... study who adopted bifocals to ease difficulties in focusing on ...
... April 29 BioElectronics,Corporation, (Pink Sheets: BIEL), announced ... the ActiPatch products to the Italian market. TSS ... both pharmacies,and consumers in Italy. TSS Medical is ... and is headquartered in Torino, Italy. Over,10,000 ActiPatch ...
... ... Characteristics of New Drugs, BOSTON, April 29 ... provider of commercial open-source "R",software for computational statistics, today released ... Quad-Core AMD,Systems," a study conducted in partnership with Pfizer on ...
... get them at the wrong time, CDC study finds , , ... more than a quarter of American toddlers may be under-vaccinated. ... months found that missed doses account for about two-thirds of ... issue, according to a study conducted by the U.S. Centers ...
... HCA announces the,following Webcast:, What: ... 9:00am CT, Where: http://www.videonewswire.com/event.asp?id=47214 , How: ... on to the web at the ... to participate during the live webcast, the call will,be archived on the ...
... management expertise to executive role, SEATTLE, April ... the appointment of John Havard as the company,s ... 21 years experience,to the Stratos team of product ... as some of the best talent,in complex technology ...
Cached Medicine News:Health News:A life 'lens' ordinary 2Health News:BioElectronics Corporation Announces New Website for Italian Market 2Health News:BioElectronics Corporation Announces New Website for Italian Market 3Health News:Pfizer Partners with REvolution Computing to Improve Medicine Production Pipeline 2Health News:Pfizer Partners with REvolution Computing to Improve Medicine Production Pipeline 3Health News:1 in 4 U.S. Toddlers Improperly Vaccinated 2Health News:1 in 4 U.S. Toddlers Improperly Vaccinated 3Health News:Stratos Product Development Welcomes Back John Havard as Vice President of Engineering 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: